Private Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$903K	Buy	2,729 +574	+27%	+$195K	0.06%	159
2025 Q4	$857K	Buy	2,155 +736	+52%	+$326K	0.07%	137
2025 Q3	$647K	Buy	+1,419	New	+$578K	0.05%	144
2023 Q1	–	Sell	-3,351	Closed	-$796K	–	201
2022 Q4	$796K	Buy	3,351 +146	+5%	+$31.1K	0.17%	101
2022 Q3	$642K	Buy	+3,205	New	+$611K	0.15%	111

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Advisory Group's ALNY Position: Q1 2026 in Review

Private Advisory Group increased its Alnylam Pharmaceuticals (ALNY) stake by 27% in Q1 2026, buying an estimated $195K and bringing the position to 2,729 shares worth $903K. The position accounts for 0.06% of the portfolio, ranked #159.

Private Advisory Group first reported a position in ALNY in Q3 2022 and has held it in 5 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Private Advisory Group held 2,729 shares of Alnylam Pharmaceuticals worth $903K as of Q1 2026.
Private Advisory Group bought 574 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $195K.
Alnylam Pharmaceuticals made up 0.06% of Private Advisory Group's portfolio in Q1 2026, its #159 holding.
Private Advisory Group first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Private Advisory Group's 13F filing for Q1 2026, filed 8 May 2026.